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Abstract:  Before reacting against non-self infectious agents, the immune system is
educated to tolerate the host molecular structure (self). The induction of self-tolerance is
a multistep process that begins in the thymus during fetal ontogeny (central tolerance)
and also involves inactivating mechanisms outside the thymus (peripheral tolerance).
The thymus is the primary lymphoid organ implicated in the development of competent
and self-tolerant T cells. During ontogeny, T cell progenitors originating from
hemopoietic tissues (yolk sac, fetal liver, and then bone marrow) enter the thymus and undergo a program of
proliferation, T cell receptor (TCR) gene rearrangement, maturation and selection. Close interactions between
thymocytes (pre-T cells) and the thymic cellular environment are crucial both for T cell development and
induction of central self-tolerance. Thymic epithelial and stromal cells synthesize polypeptides belonging to
various neuroendocrine families. The thymic repertoire of neuroendocrine-related precursors transposes at the
molecular level the dual role of the thymus in T cell negative and positive selection. Thymic precursors not
only constitute a source of growth peptides for cryptocrine signaling between thymic stromal cells and pre-T
cells, but are also processed in a way that leads to the presentation of self-antigens by thymic major
histocompatibility complex (MHC) proteins. Thymic neuroendocrine self-antigens often correspond to
peptide sequences highly conserved during the evolution of their corresponding family. The thymic
presentation of some neuroendocrine self-antigens is not restricted by MHC alleles. Following the
presentation of neuroendocrine self-antigens by thymic MHC proteins, the T cell system might be educated to
tolerate main hormone families. Recent experiments argue that a defect in the thymic essential tolerogenic
function is implicated as an important factor in the pathophysiology of many autoimmune diseases.
INTRODUCTION
The whole field of immunophysiology is
characterized by two fundamental properties. First,
the generation of diversity of the immune system
results from the random recombination in somatic
cells of gene segments coding for the variable part
of immunoglobulin (Ig) [1] B and T cell receptors
for the antigen (TCR) [2]. Secondly, even before
being able to recognize and react against non-self
antigens, the immune system is educated to
tolerate self-antigens. With memory and speci-
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ficity, diversity and self-tolerance constitute the
corner stones of immunophysiology. The
induction of self-tolerance is not an automatic
genetically programmed process, but is an
acquired multi-step phenomenon that is initiated
within the thymus during T cell differentiation [3].
In the last thirty years, close interactions were
demonstrated between the major systems of cell-
to-cell signaling, the nervous, endocrine and
immune systems. Intimate neuroendocrine-
immune interactions play a pivotal role in
homeostasis as well as in normal development of
different species. During phylogeny and ontogeny,
the molecular foundations of the signaling systems
emerge before the generation of diversity and
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specificity in the system of immune defenses. The
objective of this review is to show how such
intimate relationships between the neuroendocrine
and immune systems already take place within the
thymus, the primary organ involved in T cell
lymphopoiesis. A special emphasis will be
developed about neuroendocrine influences upon
early T cell differentiation, as well as about the
cellular and molecular mechanisms by which the T
cell system is educated to tolerate neuroendocrine
protein families. Recent observations will be
reported that argue for an impairment of thymic T
cell tolerance as an important component for the
pathogenesis of autoimmune endocrine disorders
such as Type 1 diabetes and Type 3 thyroiditis
(Graves’ disease). Finally, a rationale hypothesis is
presented that supports the design of a tolerogenic
approach based on thymic self-antigens for the
prevention of autoimmunity.
ONTOGENY AND HISTOPHYSIOLOGY OF
THE THYMUS
The thymus is a median organ in the superior
mediastinum behind the sternum, and its general
shape resembles the leaves of the ‘thyme’ plant.
The major part of the thymic parenchyme is
constituted by epithelial cells (TEC) which derive
from (a) endoderm of the third pharyngeal pouch,
and (b) ectoderm of the corresponding branchial
clefts [4, 5]. Inclusion of ectoderm explains the
heterogeneity of TEC, as well as the similar
phenotype of medullar and outer cortical TEC.
Interactions between the epithelial rudiment and
cells derived from the cephalic neural crest cells
are necessary for the development of a functional
thymic structure [6, 7]. Some human diseases and
related animal models are characterized by a
defective thymic development that leads to
primary immune deficiencies [8]. The DiGeorge’s
syndrome includes the congenital absence (or
hypoplasia) of thymus, parathyroids, and defects
in the heart and truncal vessels [9]. This syndrome
seems to result from the failure of migration of the
cephalic neural crest [10]. Mice in whom the
homeobox Hoxa-3 has been disrupted present
thymic aplasia, parathyroid hypoplasia, and
frequent defects in the heart and great vessels [11].
Wild animals with immunodeficiencies most
closely resembling those of DiGeorge’s syndrome
are ‘nude’ mice with hairlessness and lack of
thymic development both resulting from defect in
epithelial cells. The nude phenotype is caused by
mutations in a gene on murine chromosome 11
that encodes the transcription factor winged-helix
nude (whn). In the absence of whn, the thymus
rudiment still develops but is filled with primitive
epithelial cells that do not specialize and segregate
into subregions [12].
Thymic nurse cells (TNC) are large epithelial
cells found in the subcapsular and outer cortex of
the thymus in different species. TNC contain a
large number of internalized thymocytes
(immature or pre-T cells) that are not
phagocytosed, but are engulfed by emperipolesis
within caveoles delineated by TNC plasma
membrane [13]. TNC-associated thymocytes
display a high mitotic index. Functionally, TNC
are involved in T cell selection since a TNC-
derived cell line is able to induce in vitro deletion
of thymocytes bearing a transgenic TCR [14].
Ultrastructural analyses have shown that TNC
possess the intracellular machinery necessary for
antigen processing and presentation [15].
The thymic stroma also contains non-lymphoid
bone marrow-derived cellular elements:
macrophages and dendritic/interdigitating (IDC)
cells. Macrophages are dispersed throughout
thymic cortical and medullary parenchyme, while
IDC are located at the cortico-medullary junction.
The expression by macrophages and IDC of major
histocompatibility complex (MHC) class I and II
molecules is linked to their activity as dedicated
antigen-presenting cells (APC).
Thymic lymphoid cells (thymocytes) form a
‘passenger’ cell population of the thymus. First
from yolk sac and fetal liver, then from bone
marrow, T cell progenitors are attracted and
migrate within the thymus. This organ provides an
appropriate and specific microenvironment for T
cell maturation. In the thymic network, several
types of interactions between thymocytes and
parenchymatous cells trigger T cell proliferation,
TCR gene random rearrangements, differentiation
end expression of the first specific CD T cell
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markers, CD2 in humans and Thy-1 in mice. The
pathways of T cell differentiation may be followed
by the differential expression of the adhesion
molecule CD44 (Pgp-1) and the a chain of the IL-
2 receptor (CD25), the CD3/TCR complex
proteins, and the co-receptor proteins, CD4 and
CD8. Most steps of T cell differentiation occur in
the cortex, while thymic medulla contains mainly
mature T cells. From 100 T cell progenitors which
migrate into the thymus, about only 5 to 10 mature
T cells will leave it in a state of functional
competence and self-tolerance [16]. Thus, the
thymus is primarily a graveyard for T cells
harboring a randomly rearranged TCR oriented
against self-antigens encountered and presented in
the thymus.
THE THYMIC REPERTOIRE OF
NEUROENDOCRINE SELF-ANTIGEN PRE-
CURSORS
1. Thymic Neurohypophysial Self-Antigen
[See Complete Review in 17]
Though the galactogogue action of thymic
extracts had already been reported at the beginning
of this century [18], oxytocin (OT) was identified
as the primary mediator of galactokinesis only in
the early 50’s [19]. OT and vasopressin (VP) are
nonapeptides that are synthesized by distinct
neurons of the hypothalamic paraventricular and
supraoptic nuclei. Hypothalamic OT and VP
transcription is followed by mRNA translation into
larger precursors that are processed during their
axonal transport toward the neurohypophysis. This
processing gives rise to the active neurohormones
OT and VP, and their associated 10-kDa binding
proteins neurophysins. From the neurohypophysis,
OT and VP are released with neurophysins in the
bloodstream. According to the neuroendocrine
type of cell-cell signaling, they are transported in
the bloodstream to their target receptors in the
mammary myoepithelial gland and myometrium
for OT, and in the kidney collecting tubules and
vessel smooth muscle cells for VP.
The oxytocic activity of thymic extracts was
not further characterized until 1986 when
immunoreactive (IR) OT and neurophysin were
identified in the human thymus [20]. The other
neurohypophysial hormone vasopressin (VP) is
also detected in the human thymus but IR VP
concentrations are much lower (0.01-0.06 ng/g VP
vs. 2.2-18.4 ng/g OT). By immunocytochemistry
(ICC) and by in situ hybridization, TEC/TNC from
different species were shown to express
neurohypophysial genes, and the use of specific
monoclonal antibodies (mAbs) against OT and VP
revealed a dominance of OT immunoreactivity.
However, OT expression and OT synthesis in
TEC/TNC is not associated with the secretion of
the nonapeptide or neurophysin in the supernatant
of human TEC primary cultures. As another
argument against a classic neurosecretion of
thymic OT, the peptide is not located in secretory
granules but is diffuse in the cytosol, in vesicles of
the endoplasmic reticulum, or associated with
cytokeratin filaments [21]. Similar ultrastructural
features were also described for OT- and VP-
expressing murine splenic eosinophils [22].
The hypothesis that thymic OT behaves as the
self-antigen of the neurohypophysial family was
investigated through different types of
experiments. Using affinity chromatography with
a mAb to the monomorphic part of MHC class I
proteins, a 55-kDa protein was identified in a
preparation of human TEC plasma membranes.
This protein was stained both with mAb to MHC
class I and with a polyclonal Ab to neurophysin.
This protein is thought to be a hybrid protein with
a neurophysin domain (10 kDa), and a MHC class
I heavy chain domain (45 kDa) [23]. A 40-kDa
protein isolated from small-cell lung cancer with
anti-neurophysin Abs also reacted with a mouse
mAb to MHC class I. Edman degradation on this
40-kDa protein revealed a N-terminal sequence
from MHC-class I protein [24]. According to this
interpretation of a hybrid neurophysin/MHC class
I protein, the processing of thymic OT would
implicate MHC pathways for targeting to the TEC
plasma membrane. By analogy with the situation
in the hypothalamo-neurohypophysial axis, the
neurophysin domain of the thymic OT precursor
could bind and transport OT until the external
limits of OT-synthesizing TEC. If this hypothesis
were confirmed, two significant advantages would
appear in thymic T cell tolerance of the
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neurohypophysial family: (1) the absence of a
MHC allelic restriction such as in the peripheral
antigen presentation by professional APC [24],
and (2) the presentation to immature T cells of the
classic structure of neurohypophysial peptides (a
cycle of six amino acids closed by a disulfide
bridge, and a linear C-terminal part of three
residues). The antigenic behavior of thymic OT
was confirmed by the fact that the immunological
recognition of membrane OT by specific mAbs
markedly enhances the secretion of interleukin-6
(IL-6) and leukemia inhibitory factor (LIF) in
primary cultures of human TEC [26]. The
treatment of such cultures with a mAb to VP did
not induce any significant effect on IL-6 and LIF
secretion arguing for the absence of VP
presentation by thymic TEC. Additional
observations about the tolerogenic function of
thymic OT will be presented below.
2. Thymic Insulin-Related Genes
The presence of a thymic insulin-like peptide
was first reported in 1965 [27] on the basis that
AKR female mice spontaneously develop
hypoglycemia and thymic hyperplasia associated
with lymphoid leukemia. Marked hypoglycemia
was induced by injection of mouse thymic extracts
into female AKR mice, and this biological activity
exceeded the hypoglycemic potency of similarly
prepared pancreatic extracts. To the best of our
knowledge, this thymic insulin-like peptide was
not further characterized until independent
observations showing that insulin-like growth
factor (IGF) [28] and insulin genes [29] are
expressed in the thymus. Using a panel of Abs
directed against distinct insulin-related
polypeptides, ICC analyses revealed that IGF-2 is
the dominant member of the insulin family
expressed by TEC/TNC in different species [30].
The components of the IGF axis, including IGF-
binding proteins (IGFBPs), have been
characterized in the human thymus. Human TEC
express different members of the IGF axis, with a
predominance of IGF-2 and IGFBP-2 to –6 [30].
RT-PCR with specific primers showed that thymic
IGF2 transcription is controlled by the same
promoters as in other fetal and adult extrahepatic
tissues [31]. IR (pro)insulin was not detected in the
thymic parenchyme, whereas IR IGF-1 was
detected in thymic stromal cells with a
macrophage-like morphology and distribution. The
expression of IGF and IGF receptor (IGFR) genes
was investigated by RT-PCR during ontogeny of
the murine thymus. IGF1, IGF1R, M6P/IGF2R are
expressed in the thymus both in fetal and postnatal
life, whereas IGF2 transcripts decline after birth
but remain detectable on the seventh week. By in
situ hybridization, IGF2 mRNAs were located in
the outer cortex and medulla of the postnatal
thymus, in accordance with the distribution of IR
IGF-2 [32]. In the human thymus, IGF-2, IGF-1
and (pro)insulin concentrations are: 96.7 ± 10.6
ng/g, 42.9 ± 5.0 ng/g, and < 0.01 ng/g wet weight,
respectively. No secretion of IGF-2 or IGF-1 could
be evidenced in primary cultures of human TEC.
By ICC and confocal microscopy, a significant
part of IR IGF-2 (but neither IR IGF-1, nor IR
proinsulin) was detected at the outer surface of
human TEC plasma membrane. A thymic
hyperplasia is observed in transgenic mice
overexpressing IGF2 under the control of the
MHC H-2Kb promoter [33]. Altogether, these
observations argue that the thymic insulin-like
factor described by Pansky and coworkers
corresponds to IGF-2. The close homology
between IGF-2 and proinsulin may explain cross-
reactivity with polyclonal Abs to insulin that were
used in 1965. Similarly, the hypoglycemic effects
of thymic extracts may result from the binding of
thymic IGF-2 to insulin receptors. Moreover, the
syndrome of hypoglycemia and lymphoid
leukemia associated with thymic hyperplasia in
AKR female mice might result from over-
expression of IGF2 in hyperplastic thymic
epithelium leading to IGF-2 secretion into the
bloodstream and disturbed thymic T cell
lymphopoiesis.
3. Other Components of the Thymic
Repertoire of Neuroendocrine-Related Pre-
cursors
Neurokinin A (NKA) is the peptide of the
tachykinin family expressed in human and rat TEC
under the control of the preprotachykinin A gene
(PPT-A) [34]. NKA is known to exert IL-1-like
mitogenic effects on murine thymocytes [34]. The
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ß and g  forms of PPT-A mRNA also encodes
substance P (SP) in the brain, but this tachykinin is
not detected in thymic epithelium suggesting a
differential processing or translation of PPT-A
mRNA in neurons and TEC. Interestingly, while
IR NKA has been identified in TEC, IR SP was
detected only in nerve profiles associated with
thymic blood vessels. Since high affinity SP
receptors have been described in association with
vascular structures of rat thymic medulla [36], it is
likely that neuronal SP regulates local blood flow.
IR neurotensin (NT) and somatostatin have
been identified in sparse stromal cells of the
chicken thymus [37]. Primary cultures of human
TEC contain ± 5 ng/g IR NT/106 cells, of which
2.5-5% is associated with TEC plasma
membranes. However, IR NT was not detected in
the culture medium further questioning the classic
neurosecretory model for thymic epithelium.
Using anti-MHC class I affinity chromatography
followed by HPLC analysis, one peak of IR NT
was eluted at the same position as synthetic NT1-13,
together with two other NT C-terminal smaller
fragments [38].
THYMIC NEUROENDOCRINE PEPTIDES
AND T CELL DEVELOPMENT
1. Thymic OT and Focal Adhesion
The active role of thymic OT in a cryptocrine
type of signaling between TEC and thymocytes
was first evidenced by the expression of specific
neurohypophysial binding sites by murine pre-T
RL12-NP and cytotoxic CTL-L2 cell lines. These
binding sites behave as functional receptors since
they transduced neurohypophysial signals through
the phosphoinositide pathway [39]. The molecular
identity of these neurohypophysial receptors
remains to be further precised (OT or a V1-
subtype), and this point is under current
investigation. Nevertheless, the KD of these
receptors concords with the concentration of IR
OT quantified in the human thymus, and
mitogenic properties of neurohypophysial peptides
are associated with the increase of inositol
phosphates in pre-T cells [39]. A very recent study
has underlined the importance of phosphoinositide
3-kinases in T cell development and activation, as
well as neutrophil migration (but without any
significant role in the development and function of
B cells) [40].
The observation of numerous points of focal
adhesion between OT-producing TEC and pre-T
cells [21] prompted us to investigate the potential
implication of the recently discovered focal
adhesion-related kinase p125FAK [41]. Protein
tyrosine phosphorylation is known to be an early
event in T cell activation. Western analysis of
RL12-NP proteins probed with with anti-
phosphotyrosine (PY-20) revealed a number of
proteins the phosphorylation of which increased
after OT or VP treatment. OT-mediated
phosphorylation was rapid and reached a
maximum within 1-5 min. OT also was more
potent than VP to induce phosphorylation in
RL12-NP cells. Two of these proteins were
precipitated with anti-FAK mAb 2A7 and were
identified one as p125FAK and the other as a
coprecipitated 130-kDa protein (most probably
p130Cas) [42]. A neurohypophysial V1 antagonist
inhibited OT-induced phosphorylation of p125FAK,
which demonstrates the specificity of this action
but also questions the identity of the natural
neurohypophysial ligand for V1 receptors
expressed by T lymphocytes. Another protein
phosphorylated by OT in pre-T cells was identified
as paxillin, a 68-kDa protein located at focal
adhesion sites in association with p125FAK [42].
Since T cell differentiation depends on close
interactions and adhesion between thymic stromal
cells and thymocytes [43], the implication of focal
adhesion kinases in this process surely deserves to
be further investigated. Altogether, these
observations largely document the model of
cryptocrine signaling proposed to distinguish the
chemical communication between TEC/TNC and
immature T cells that migrate and differentiate at
their contact [44].
2. Thymic IGFs and T Cell Differentiation
Murine fetal thymic organ cultures (FTOCs) are
an appropriate in vitro model for the study and
manipulation of T cell differentiation [45-47]. The
thymus removed from murine embryos on the 14th
fetal day contains the epithelial rudiment and only
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immature T cell progenitors. After seven days in
culture, pre-T cells differentiate along usual
pathways. Thus, FTOCs closely mimic
physiological conditions of in vivo T cell
differentiation. Briefly, the phenotype of early T
cell progenitors is double negative for the
expression of CD4 and CD8 (CD4-CD8-). Then,
they become double positive (CD4+CD8+),
acquire CD3, and finally turn into the single
positive cells expressing either CD4 or CD8. With
the characterization of the thymic IGF axis,
several observations have been reported
supporting the implication of IGFs in T cell
development. Thymocytes express both types of
IGF receptors (IGF-1R and M6P/IGF-2R) [48-50].
Administration of IGF-1 stimulates stimulates
lymphopoiesis and modulates the regeneration of
T lymphocytes in a rat model of dexamethasone-
induced apoptosis [51, 52]. The thymus of IGF2
transgenic mice displays an increase thymic
cellularity, with a higher number of the CD4+ T
cell subset [53]. FTOC treatment with an anti-IGF-
2 mAB, an anti-IGF-1R, or an anti-M6P-IGF-2R
polyclonal Ab induced a blockade of T cell
differentiation at the CD4-CD8- stage. This was
evidenced by an increase of CD4-CD8- cells and a
parallel decrease in the percentage of CD4+CD8+
thymocytes. Anti-IGF-2 Ab also induced an
increase in CD8+ cells suggesting that thymic
IGF-2 might have a role in determining
differentiation into the CD4 or CD8 lineage. The
strongest effects upon T cell proliferation and
differentiation were observed in FTOCs treated
with anti-IGF-1R mAb. Anti-IGF-1 Ab decreased
the percentage of CD4-CD8- cells and increased
the frequency in CD4+CD8+. Though the
proinsulin gene is transcribed in the murine
thymus [25, 54], FTOC treatment with anti-
(pro)insulin did not exert any significant effect on
T cell differentiation. As shown by these data, the
intrathymic IGF-mediated signaling plays an
active role in T cell differentiation during
ontogeny [32].
THE NATURE OF SELF: THYMIC
NEUROENDOCRINE SELF-ANTIGENS AND
SELF-TOLERANCE
During their thymic differentiation, immature T
cells randomly rearrange the gene segments
coding for the variable part of their TCR. Many of
these TCR recombinations are oriented against
self-antigens expressed and presented by MHC
proteins in the thymic microenvironment. The
interaction of self-reactive T cells with their
cognate self-antigens is thought to lead to their
negative selection either by programmed cell death
(apoptosis) or by developmental arrest. Thymic
clonal deletion was demonstrated using mouse
mammary tumor virus (MMTV)-encoded
superantigens [55], and with transgenic mice
expressing a TCR specific for the male antigen H-
Y [56]. Self-antigens are not only involved in the
induction of central T cell self-tolerance but also
intervene in the process of T cell maturation and
positive selection [57]. The ‘avidity-affinity’
hypothesis has been proposed to explain this major
paradox of thymic physiology, i.e. how self-
antigens are able to condition both the death and
the survival of T cells ? According to this
hypothesis, T lymphocytes are deleted if their
TCR is strongly engaged with a self-antigen at
high concentrations (10-6 M). On the contrary, they
are positively selected if their TCR is barely
engaged with self-peptide at low concentrations
(10-12 M) [58, 59]. However, the affinity of a TCR
for its cognate antigen is rather low (10-8 M at
maximum). Thus, it is now of crucial importance
to know the nature and the amount of
peptide/MHC combinations that contribute in vivo
to T cell negative and positive selection [60].
As another explanation to this paradox, it has
been proposed that the thymic repertoire of
neuroendocrine-related precursors recapitulates at
the molecular level the dual role of the thymus in
T cell selection [61]. Thymic polypeptide
precursors engage two distinct types of
interactions with pre-T cells depending on their
behaviour either as cryptocrine growth signals or
as self-antigens representative of their family.
Cryptocrine signaling implies a high-affinity (10-12
M) but poorly specific binding of thymic
neuroendocrine peptides to their cognate receptors
expressed by pre-T cells. Such cryptocrine
signaling has been shown to exist and to be
mediated by OT and IGF-2 in the thymus network.
Recently, other authors have also discussed the
point that thymocyte selection cannot be explained
Central Self-Tolerance by Thymic Presentation Curr. Med. Chem. – Imm., Endoc. & Metab. Agents, 2001, Vol. 1, No.1    7
by interaction with TCR alone [62]. On the other
hand, neuroendocrine self-antigens bind to their
corresponding TCR with a moderate affinity (10-8
M), but with a high specificity. This latter
interaction is thought to induce the central T cell
tolerance of neuroendocrine families.
Neuroendocrine self-antigens usually correspond
to peptide sequences of neuroendocrine precursors
highly conserved throughout evolution of a given
hormone family. Moreover, a hierarchy of
dominance has been shown in the organisation of
the neuroendocrine polypeptide repertoire
expressed in the thymus. This hierarchy is highly
significant since self-tolerance primarily concerns
self-antigenic determinants that are dominant on
self-proteins [63, 64]. Thus, even if some members
of a family (i.e. VP or proinsulin) are detected at
very low levels in the thymus, the thymic
tolerogenic function firstly concerns their
homologous dominant thymic growth factors (i.e.
OT or IGF-2, respectively). Through the central
tolerance of the dominant factor however, the
immune system could be educated to tolerate the
whole family.
The tolerogenic properties of OT and IGF-2
have not been definitively proved. However, OT-
mediated functions are known to be stronger
tolerated than the VP-mediated ones. Some cases
of ‘idiopathic’ central diabetes insipidus result
from an autoimmune hypothalamitis directed
against VP-producing neurones [65, 66]. Given the
implication of OT as a reproductive hormone, a
stronger tolerance of the OT lineage is crucial for
the preservation of the species. This conclusion is
indirectly supported by the frequence and the titers
of Abs obtained from active immunization
(equivalent to tolerance breakdown) against
neurohypophysial hormones (VP >> OT). Similar
conclusions were drawn from active immunization
against insulin, IGF-1 and IGF-2 (see after). Thus,
in the neurohypophysial peptide family, while OT
behaves as the self-antigen, VP is strongly
suspected to be the autoantigen targeted by the
autoimmune process leading to some forms of
central diabetes insipidus. In the insulin hormone
family, insulin is a major autoantigen of the
autoimmune process against insulin-secreting islet
ß cells, and insulin immunogenicity might result
from its very low expression in the thymus
network.
Using RT-PCR, in situ hybridization and ICC,
we recently investigated the ontogeny of
neurohypophysial gene expression in the thymus
of Balb/c mice. Transcripts of OT and VP were
detected without any visible modulation in the
thymus already from fetal day (FD) 14 until day 7
after birth [67]. In the murine thymus,
neurohypophysial trancripts are located in cells
with an epithelial morphology and are absent in
the lymphoid compartment. Because of the
microscopic size of thymic rudiments before
FD 14, it was not possible to analyze the earlier
thymic expression of neurohypophysial genes.
Nevertheless, the comparison with previous
reports shows that the transcription of
neurohypophysial genes in the rodent thymus
precedes their expression in the magnocellular
neurones of the hypothalamic-neurohypophysial
axis. At the peptide level, this difference is more
evident since IR OT is detected in the thymus on
FD 15, whereas ICC labels IR OT in the
hypothalamus only on FD 20. Thus, the expression
of neurohypophysial genes in the murine thymus
coincides with the appearance of T-cell
progenitors and precedes their hypothalamic
transcription. This observation is significant with
regard to the physiological role proposed for
thymic OT as a self-antigen involved both in T cell
lymphopoiesis and in central tolerance of the
hypothalamo-neurohypophysial functions. Indeed,
it is logical that the induction of central self-
tolerance precedes the appearance of antigenic
epitopes in target organs susceptible to
autoimmune aggression.
THYMUS DYSFUNCTION AND AUTO-
IMMUNITY
Though the relationship between
lymphoepithelial structures and autoimmunity has
been suspected already in 1962 by Burnet and
Mackay [68], the question of a defective central T-
cell self-tolerance in the pathophysiology of
autoimmune diseases has not been intensively
investigated. Also, Burnet proposed that the
emergence of ‘forbidden’ self-reactive clones
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plays a major role in the pathophysiology of
autoimmunity. These ‘forbidden’ self-reactive
clones were initially thought to result from somatic
mutations during development. Since the whole
immune repertoire is generated by somatic random
recombination, this hypothesis is no longer
tenable. However, some ‘holes’ in the peripheral T
cell repertoire could appear if some self-reactive
lymphocytes would not be deleted by their cognate
self-antigen.
Neonatal thymectomy prevents the emergence
of diabetes in an animal model of autoimmune
Type 1 diabetes, the Bio-Breeding (BB) rat [69].
In clinical practice also, thymectomy induces a
significant improvement of patients suffering from
autoimmune myasthenia gravis [70]. In both cases,
the benefit of thymectomy may be explained by
the removal of the defective thymic censorship. At
least theoretically, such a trouble in thymic self-
tolerance would be responsible for a continuous
release and enrichment of the peripheral T-cell
pool with intolerant and ‘forbidden’ self-reactive
lymphocytes. The transplantation of the defective
thymus from non-obese diabetic (NOD) mice to
athymic nude mice induces autoimmune insulitis
in the recipient [71]. On the contrary, the
development of autoimmune diabetes is prevented
by the transplantation of thymus from diabetes-
resistant to diabetes-prone BB rats [72]. Recently
also, insulitis and sialitis developed in athymic
nude mice grafted with pure thymic epithelium
from NOD mice [73]. Some studies also suggest
that thymic epithelium not only mediates negative
selection of self-reactive T cells, but also selects
regulatory T cells helping in maintaining tissue-
specific self-tolerance [74].
1. Autoimmune Type 1 Diabetes (Fig. 1)
More and more, the breakdown of
immunological tolerance of insulin-secreting islet
ß cell is thought to be a major event in the
pathophysiology of autoimmune Type 1 diabetes
and several putative ß cell autoantigens have been
identified [75]. In this cohort of autoantigens,
insulin (and/or its precursor proinsulin) is specific
Fig. (1). Role of the thymus in the pathophysiology of autoimmune Type 1 diabetes.
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of the islet ß-cell-related autoantigens and plays an
important role in the development of this chronic
devastating disease. However, despite the
identification of ß-cell antigens, the origin of self-
reactivity in Type 1 diabetes remains unexplained.
Noteworthy, a defect of thymic epithelium was
previously observed in BB rats and NOD mice
[76, 77]. This epithelial defect was proposed to
intervene in the dysfunction of thymic T cell
differentiation and susceptibility to autoimmune
diabetes. To investigate the hypothesis of a defect
in thymic T cell self-tolerance of the insulin family
in that disease, a comparative study of thymic
IGFs and insulin (INS) gene expression was
performed in BB rats. The absence of thymic IGF2
expression was evidenced in more than 80% of
diabetes-prone BB rats, while IGF1 and INS
mRNAs were detected in Wistar-Furth, diabetes-
resistant and diabetes-prone BB rats. This defect
was thymus-specific since diabetes-prone BB rat
brains and livers express readily detectable IGF2
mRNA. The defect was shown both at the IGF2
transcript and IGF-2 protein levels. The absence of
IGF2 expression in the thymus of young and adult
diabetes-prone BB rats might have a role in the
defect of central self-tolerance of the insulin
hormone family and contribute to the
pathophysiology of autoimmune Type 1 diabetes
[78; manuscript submitted]. Interestingly, the
region containing the IGF2 locus on chromosome
1 in spontaneously diabetic BB rats is a protective
locus [79], but is also associated with blood
glucose in diabetic rats [80].
A recent debate was opened about the relative
contribution of thymic IGF-2 and insulin to self-
tolerance of the insulin family. The IDDM2 locus
of susceptibility to diabetes maps to a variable
number of tandem repeats (VNTR) mini-satellites
on chromosome 11p15, upstream of INS and IGF2
genes [81]. However, there exists some
controversy about the precise boundaries of
IDDM2 [82]. Short class I VNTR alleles (26-63
repeats) predispose to Type 1 diabetes, whereas
long class III alleles (140-210 repeats) are
dominantly protective [83]. Two independent
studies reported that higher levels of INS mRNA
were associated with the protective class III VNTR
alleles of the IDDM2 locus [84, 85]. The
susceptibility locus VNTR is also associated with
IGF2 expression in humans [86], though no
significant influence of VNTR susceptibility (class
I) or protective (class III) alleles could be
evidenced on IGF2 transcripts in the human fetal
thymus [87]. Besides this association, the
tolerogenic effect of thymic insulin has been
deduced from its expression in dendritic cells that
are professional antigen-presenting cells.
The pattern of immune reactivity generated by
IGF-2 has not been investigated until now. With
regard to the cellular site of INS and IGF2
expression, both thymic dendritic and TEC are
able to present antigens. Functionally, the
dominance and crypticity of T-cell epitopes [88]
determine the final orientation of an antigen-
driven response, towards either priming or
tolerizing. Thus, if a tolerogenic response indeed
follows the intrathymic expression of an insulin-
related protein, this firstly concerns the dominant
peptide of this family. Thymic IR (pro)insulin
concentrations (± 2 pmol/mg protein) are much
lower than thymic IR IGF-2 (± 100 ng/g wet
weight), and it is known that thymic tolerance
rapidly decreases for peptide concentrations below
10 nM [58, 59]. As another question to the
physiological significance of thymic insulin,
FTOC treatment with a mAb to (pro)insulin does
not influence T-cell differentiation [32]. The
crucial role of IGFs in fetal and postnatal
development implies that these growth factors
must be strongly protected from an autoimmune
attack. As an important though indirect argument
for the tolerogenic properties of IGF-2, the
production of specific Ab is much more difficult
with IGF-2 than with IGF-1 or insulin [89]. IGF-2
protein contains peptide sequences highly
conserved during evolution of the insulin family
[90]. Through this homology, thymic IGF-2 would
be a good candidate for inducing central
immunological tolerance of the insulin family
although the tolerance of insulin per se would be
weaker. This might explain why B- and T-cell
reactivity to insulin has been observed in diabetic
and non-diabetic individuals [91]. Contrary to
other autoantigens implicated in Type 1 diabetes
(like GAD 65 and phosphatase IA-2), insulin is
specifically synthesized and secreted by islet ß
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cells, and insulin is considered as a critical target
of the autoimmune diabetogenic process [92].
Insulin is also the only autoantigen whose gene
maps to a diabetes susceptibility locus [83]. Again,
insulin immunogenicity might result from its very
low expression in the thymus network. Oral,
intranasal and parenteral administration of insulin
has been shown to inhibit the occurrence of
diabetes in NOD mice [93], but the same treatment
is ineffective [94], or even promotes disease in
diabetes-prone BB rats [95]. Thus, current insulin-
based preventive strategies cannot ignore the risk
of priming autoimmune Type 1 diabetes as a result
of autoantigen administration [94]. A crucial
question also concerns both the existence and the
putative diabetogenic role of ‘forbidden’ IGF-2
self-reactive T cell clones. This question will be
examined using IGF2-deleted mice in whom IGF-
2 is no more a self-antigen so that tolerance of
IGF-2 should be very low. The problem is
nevertheless quite complicated since IGF2 is
subject to tissue-specific parental imprinting in
mice as in humans [97-99].
2. Autoimmune Type 3 Thyroiditis (Graves’-
Disease)
The pathogenesis of autoimmune thyroid
diseases involves several thyroid antigens
including human sodium iodide symporter,
thyrotropin receptor (TSH-R), thyroid peroxydase
(TPO) and thyroglobulin (Tg) [100]. Auto-Abs to
TSH-R exerting thyroid stimulation by recognition
of TSH-R are responsible for the state of
hyperthyroidism in autoimmune Type 3 thyroiditis
or Graves’disease [101]. Thyroid-associated
orbitopathy and pretibial myxedema are
commonly associated in Graves’disease and TSHR
and/or a TSHR variant [102] was shown to be
expressed in orbital tissues [103] and in pretibial
fibroblasts of patients with Graves’disease [104].
T cell recognition of TSH-R peptide sequence
158-176 is thought to be an early event in the
initiation of the autoimmune process leading to
Graves’disease [105]. During their thymic
development, T cells can be educated to tolerate
thyroid-related epitopes since a TSH-R variant
[106], TSH-R itself, and other thyroid antigens
[106-108] are expressed in the human thymus. The
failure of thymic T cell tolerance of thyroid
antigens has not been demonstrated, but this
hypothesis is supported by the increased thymic
size and density observed by computed
tomography in patients with Graves’disease [107].
CONCLUSIONS AND PERSPECTIVES IN
TOLEROGENIC VACCINATION
The thymic repertoire of neuroendocrine self-
peptide precursors recapitulates at the molecular
level the dual physiological role played by the
thymus in T cell positive and negative selection.
Thus, this model provides some answer to the
thymic paradox in T cell development and
deletion. During the last fifteen years, the
advancement of our common knowledge in
thymus physiology has been impressive. It is not
unreasonable to consider that the natural
tolerogenic properties of the thymus could be
useful in organ transplantation (including
xenotransplantation) the ultimate goal of which is
complete tolerance between the donor and the
recipient [109, 110]. In addition, more and more
experimental observations suggest that a defect in
the active establishment of thymic T cell self-
tolerance is implicated as a crucial event in the
pathogenesis of organ-specific autoimmune
diseases. As already claimed by Lederberg in 1959
[111], the most efficient way to deal with
autoimmunity is to delete it. Of course, it is neither
useful nor even ethical to propose thymectomy for
the prevention or treatment of chronic autoimmune
diseases. Nevertheless, the identification of
neuroendocrine self-antigens that are presented by
thymic MHC proteins could be useful to provoke
deletion or inactivation of ‘forbidden’ self-reactive
T cell clones that have escaped the induction of
thymus self-tolerance (Fig. 2). While autoantigens
are the drivers of autoimmune process, thymic
self-antigens could be used to reprogram self-
tolerance, and peptide vaccination is able to induce
T cell tolerance [112, 113]. In addition to classic
immunogenic vaccination, perhaps will we have
soon at our hand tolerogenic vaccination for the
prevention of autoimmunity, the heavy tribute
mainly paid by the human species for the
specificity and diversity of its immune system.
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